Phase III Randomized Study of All-Trans Retinoic Acid versus Cytosine Arabinoside and Daunorubicin as Induction Therapy for Patients with Previously Untreated Acute Promyelocytic Leukemia
Research committees
Publication Information Expand/Collapse
2014
Telomere length recovery strongly predicts overall survival in acute promyelocytic leukemia (http://www.bloodjournal.org/content/124/21/2375)
2011
Late relapses following ALL-transretinoic acid for acute promyelocytic leukemia are uncommon, respond well to salvage therapy and occur independently of prognostic factors at diagnosis: longterm follow-up of North American Intergroup study 0129
2010
Does microgranular variant morphology of acute promyelocytic leukemia independently predict for a less favorable outcome compared with classical M3 APL? A joint study of North American Intergroup and PETHEMA Group [PMID20858857;PMC3031411]
2006
Relapse of acute promyelocytic leukemia with PML-RARx mutant subclones independent of proximate all-trans retinoic acid selection pressure
2005
Phase III trial of all-trans retinoic acid (ATRA) vs daunorubicin (D) and cytosine arabinoside (A) as induction therapy and ATRA vs observation as maintenance therapy for children with newly diagnosed acute promyelocytic leukemia (APL)
Very poor survival of patients with AML who relapse after achieving a first complete remission: the Eastern Cooperative Oncology Group experience.
2004
Microgranular variant (M3V) of acute promyelocytic leukemia (APL) does not have a worse prognosis than classical APL in the atra era: a report of 153 patients treated on Intergroup 0129 and pethema LPA96 and LPA99.
2002
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol
2001
The significance of trisomy 8 in myeloid leukemia: a Southwest Oncology Group (SWOG) study.
Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARa mRNA using real-time reverse-transcription polymerase chain reaction
2000
Glutathione S-transferase theta 1 gene deletion and risk of acute myeloid leukemia
Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARa isoform: results from Intergroup protocol 0129
Predictive value of automated, quantitative real-time RT-PCR performed at the end of consolidation of acute promyelocytic leukemia (APL): a SWOG, CALGB, and ECOG Intergroup study (INT-0129)
Hypergranular promyelocytic leukemia: correlation between morphology and chromosomal translocations including t(15;17) and t(11;17)
1999
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome results and prognostic factor analysis from intergroup protocol 0129
1998
Cell cycle arrest and therapeutic sensitivity in de novo AML.
1997
Association of PML-RARa fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: An intergroup molecular study.
All-trans-retinoic acid in acute promyelocytic leukemia.
1996
Correlation of PML-RARa mRNA transcript type with morphology, cytogenetics and clinical parameters in actue promyelocytic leukemia.
Molecular characteristics and clinical features of adult APL patients with the type V PML-RARa ISOFORM: Results from intergroup protocol 0129.
1995
Correlation of PML-RARa mRNA type with pretreatment clinical characteristics and achievement of complete remission (CR) in acute promyelocytic leukemia (APL): An Intergroup Laboratory study.
Phase III randomized study of all-trans retinoic acid (ATRA) vs daunorubicin (D) and cytosine arabinoside (A) as induction therapy and ATRA vs observation as maintenance therapy for patients with previously untreated acute promyelocytic leukemia (APL).